



ALASKA VACCINE ASSESSMENT PROGRAM

ANNUAL REPORT

2022 - 2023

Dear Friends and Colleagues,

I am happy to report that AVAP remains a highly successful program, resulting in consistent financial stability and improved access to life-saving vaccines for Alaskans.

We are delighted to inform you that the Alaska Department of Health has successfully received the entire TRICARE settlement amount of \$2.9 million. The final payment of \$1 million was received in February 2023.

I am grateful for the outstanding partnerships we have developed with key partners that support this program, the commitment of our payers in providing financial support for another robust year of AVAP operations, and the strong work of the Immunization Program staff in improving vaccine access statewide.

Joe McLaughlin, MD
Chairman

State Epidemiologist and Chief, Section
of Epidemiology, Division of Public Health,
Department of Health

WWW.AKVACCINE.ORG

A POWERFUL MODEL

Vaccine costs continue to rise nationally. AVAP's work to stabilize vaccine funding has played a crucial role in ensuring all Alaska children and adults have access to recommended vaccines.

Our model has powerful benefits:

- **No Provider Financing costs.** Instead of fronting significant dollars to keep vaccines on hand, providers receive and administer vaccines from the Alaska Department of Health (DOH).
- **Consolidated Storage and Ordering.** Providers can avoid navigating complex ordering systems based on who paid for them or who they will immunize. DOH provides support for one vaccine ordering process, regardless of the patient's insurance status.
- **Stable Vaccine Supply.** Providers can focus on patient needs and have the full complement of recommended vaccines on hand.
- **Healthcare Savings.** DOH's bulk purchase of vaccines provides significant cost savings versus the private market.

Strong Financial Performance

AVAP continues to perform extremely well thanks to the extraordinary work of Alaska's Immunization Program. Both children and adults have continued access to routinely recommended and COVID vaccines. The payer community has consistently complied through the pandemic and provided stability to AVAP during otherwise uncertain times. Payer reliability is the cornerstone of AVAP's remarkably stable operation.





AVAP Council Members

Joe McLaughlin, MD, Chairman
State Epidemiologist and Chief, Section of Epidemiology, Division of Public Health, Department of Health

GOVERNMENT REPRESENTATIVES

Sarah Bailey, AIE
Supervisor
Life / Health Filings & Market Conduct
Division of Insurance

HEALTH CARE PROVIDER REPRESENTATIVES

Patricia Clay, MD, MPH
Pediatrician
LaTouche Pediatrics

Jennifer Perkins, MD
Family Medicine
Southcentral Foundation

HEALTH CARE INSURER REPRESENTATIVES

Pamela Andrews Sheffield, MD
Medical Director, Clinical Solutions
Pacific NW Medical Health Services
Aetna

Mike Patton
Director of Large Group Underwriting
Premera

Patrick Shier
Alaska Membership Representative
Pacific Health Coalition

TRIBAL REPRESENTATIVE

Christina Eldridge, PharmD, MPH, BCACP
Outpatient Pharmacy Manager
Alaska Native Tribal Health Consortium

WWW.AKVACCINE.ORG

ADMINISTRATOR:



PHONE: 1-855-KidsVax (543-7829)

WEBSITE: www.KidsVax.org

KIDSVAX® STAFF

Seema Mack
Executive Director of AVAP

Heather Veen
Chief of Staff

Megan Conrad
Controller

Fred L. Potter
Founding Member

A message from Sarah Aho, Alaska's Immunization Manager

This year, the Immunization Program is focusing on improving routine immunization coverage rates statewide through media campaigns, monthly Alaska Vaccine ECHO sessions for health care providers, reminder recall efforts, and published reports such as Epidemiology Bulletins and quarterly reports.

Looking ahead this fall, COVID-19 vaccines will be integrated into the formulary and will be available through AVAP when the vaccines move to the commercial market. This will facilitate continued access to COVID-19 vaccines through AVAP.

Furthermore, RSV vaccines currently in development will likely be available this fall, as well as a PCV20 vaccine for children.

As we forge ahead, our focus remains on improving vaccine access and immunization coverage rates. We are happy to report that we continue to see more health care providers enrolled with AVAP each year. More uninsured adults are covered through AVAP in 2023 compared to 2022. By broadening our provider network, we are ensuring that vaccines are readily available and easily accessible to a larger portion of the Alaska population. We are continually grateful for the strong partnership and support from the AVAP Council, insurance companies and other payers, health care providers, and vaccination advocates throughout the state.




FINANCIALS

January - December, 2022


Revenues

\$ 11,968,353



Expenses

\$ 10,326,108



- 40.3% Child Assessments
- 12.2% Adult Assessments
- 1.9% Provider Opt-In Payments
- 46.8% Cash Reserves Utilized
- -1.2% Investment Loss

- 74.9% Child Vaccines
- 18.5% Adult Vaccines
- 3.2% DHSS Administrative Fee
- 3.3% KV Contract
- 0.2% Other